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Abstract: The diabetes epidemic continues to grow unabated, with a staggering toll in 
micro- and macrovascular complications, disability, and death. Diabetes causes a two- to four-
fold increase in the risk of cardiovascular disease, and represents the first cause of dialysis 
treatment both in the UK and the US. Concomitant hypertension doubles total mortality and 
stroke risk, triples the risk of coronary heart disease and significantly hastens the progression 
of microvascular complications, including diabetic nephropathy. Therefore, blood pressure 
reduction is of particular importance in preventing cardiovascular and renal outcomes. Successful 
antihypertensive treatment will often require a combination therapy, either with separate drugs 
or with fixed-dose combinations. Angiotensin converting enzyme (ACE) inhibitor plus diuretic 
combination therapy improves blood pressure control, counterbalances renin-angiotensin system 
activation due to diuretic therapy and reduces the risk of electrolyte alterations, obtaining at 
the same time synergistic antiproteinuric effects. ACE inhibitor plus calcium channel blocker 
provides  a significant additive effect on blood pressure reduction, may have favorable metabolic 
effects and synergistically reduce proteinuria and the rate of decline in glomerular filtration rate, 
as evidenced by the GUARD trial. Finally, the recently published ACCOMPLISH trial showed 
that an ACE inhibitor/calcium channel blocker combination may be particularly useful in reducing 
cardiovascular outcomes in high-risk patients. The present review will focus on different ACE 
inhibitor combinations in the treatment of patients with type 2 diabetes mellitus and hypertension, 
in the light of recent clinical trials, including GUARD and ACCOMPLISH.
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Introduction
The diabetes epidemic continues to grow.1 In the year 2000, there were an estimated 
171 million patients worldwide with a diagnosed diabetes, and this number is projected 
to rise to 366 million in 2030,2 90% of whom will have a type 2 diabetes. At the time 
of diagnosis, about 50% of type 2 diabetics are also hypertensives. This percentage 
increases even more in the presence of micro- or macroalbuminuria.3 Microalbuminuria 
(urinary albumin excretion of 20 to 200 µg/min or 30 to 299 mg/24 hours), which 
often heralds the onset of diabetic nephropathy, independently predicts cardiovascular 
morbidity and mortality in diabetic patients.4–6
Blood pressure (BP) reduction is a major priority in preventing clinical events in 
patients with type 2 diabetes mellitus and hypertension, who are at very high risk of 
cardiovascular and renal outcomes. Diabetes causes a two- to fourfold increase in the 
risk of cardiovascular disease,7,8 including stroke,9 atrial fibrillation, flutter, coronary 
heart disease (CHD) and left ventricular hypertrophy,10 and it is the first cause of renal Vascular Health and Risk Management 2009:5 412
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replacement therapy both in the UK11 and the US,12 where 
over 40% of dialyzed patients are diabetics. Concomitant 
hypertension doubles total mortality and stroke risk, triples 
the already high risk of CHD and significantly hastens the 
progression of diabetic nephropathy,13 retinopathy14 and 
neuropathy.15 In such patients, a difference of 5 mmHg 
in either systolic blood pressure (SBP) or diastolic blood 
pressure (DBP) increases the risk of cardiovascular events or 
death by 20% to 30%.16 As a consequence, the Joint National 
Committee on the Prevention, Detection, Evaluation and 
Treatment of High Blood Pressure,17 the European Society of 
Hypertension6 and the American Diabetes Association18 all 
recommend achieving a target of 130/80 mmHg in subjects 
with diabetes and hypertension.
Successful treatment of these patients will often require 
a combination therapy,19 either with separate drugs or with 
fixed-dose combinations.
Both of these offer several advantages: first, they allow 
a tighter BP control, and consequently a greater reduction of 
clinical endpoints, minimizing at the same time the risk of 
adverse effects, by using relatively small doses of two drugs 
in combination or by selecting agents that counteract each 
other’s side effects.20 As showed by an extensive analysis 
of 354 randomized trials of the five main categories of 
BP lowering drugs,21 antihypertensive efficacy of drugs in 
combination was additive, but prevalence of adverse effects 
was less than additive. In 66 trial arms, single drugs caused 
symptoms in 5.2% of participants (3.6%–6.6%), while in 
33 trial arms two drugs together caused symptoms in 7.5% 
(5.8%–9.3%), which is significantly lower than the value 
of 10.4% (twice 5.2%) expected with an additive effect 
(p = 0.03).
Secondly, in many cases less time is required to achieve 
target BP, with equivalent22 or better23 tolerability than higher 
dose monotherapy. Finally, patients with comorbidities, such 
as type 2 diabetes and hypertension, may benefit from the 
effects of different antihypertensive combinations, that may 
offer specific cardio-, vasculo- and renoprotective advantages 
that go beyond BP reduction per se.
Fixed-dose combination therapy simplifies the treatment 
regimen, improving compliance and preventing treatment 
failures caused by missed doses.24 Moreover, it usually allows 
cost reductions to the health care system.23 On the other hand, 
it is not always possible to achieve the same medications and 
dosages in a combined pill, fixed-dose combinations do not 
allow easy dose adjustment,25 exposing patients to the risk of 
orthostatic hypotension (ie, older patients, diabetic autonomic 
neuropathy), and tablet size is sometimes excessive.26
Combination therapy with separate drugs makes it easy 
to obtain the desired dose, and adjust it when needed. How-
ever, potential disadvantages include patient’s perception 
that taking more medications is equated with being sicker,25 
and generally increased costs.
In hypertensive type 2 diabetics, commonly used combination 
therapies include an angiotensin converting enzyme (ACE) 
inhibitor or an angiotensin receptor blocker (ARB) plus a diuretic 
or a calcium channel blocker (CCB). In the present review, we 
will focus on two combinations:
1.  ACE inhibitor plus diuretic
2.  ACE inhibitor plus CCB
ACE inhibitor plus diuretic
Rationale of the combination
ACE inhibitors were able to decrease cardiovascular morbidity 
and mortality in the diabetic cohort of a number of trials, 
including the Heart Outcomes Prevention Evaluation Trial,27 the 
Captopril Prevention Project Trial (CAPPP),28 the Fosinopril 
versus Amlodipine Cardiovascular Events randomized Trial 
(FACET),29 the Appropriate BP Control Diabetes (ABCD) 
Trial30 and the UK Prospective Diabetes Study,19 even if a 
meta-analysis of the Blood Pressure Lowering Treatment 
Trialists’ Collaboration (BPLTTC) demonstrated the primary 
importance of BP lowering for reducing cardiovascular risk 
in patients with or without diabetes mellitus, independently of 
drug classes.31 In any case, renin-angiotensin system (RAS) 
blockade may delay deterioration in glomerular filtration 
rate (GFR) and progression of albuminuria,32,33 and the 
renoprotective effects of RAS blockade have been shown in 
a number of landmark trials in patients with type 2 diabetes 
mellitus;34–36 comparative data from the Diabetics Exposed 
to Telmisartan And EnalaprIL Trial (DETAIL) established 
that the ACE inhibitor enalapril and the ARB telmisartan 
conferred similar renoprotection in patients with hypertension 
and early type 2 diabetic nephropathy.37 However, RAS 
blockade may inhibit urinary potassium excretion, and 
hyperkalemia remains a clinician’s major concern particularly 
in patients with or at risk for chronic kidney disease.38
Diuretics (usually thiazides or thiazide-like indoline 
diuretics such as indapamide) remain among the most effec-
tive treatments for elevated BP.17 In the aforementioned 
BPLTTC analysis,31 diuretics appear to reduce cardiovascular 
events to a degree similar to ACE inhibitors, beta-blockers 
or CCBs. Moreover, in 13 101 adults with hypertension 
and type 2 diabetes, enrolled in the Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack 
Trial (ALLHAT), a thiazide-type diuretic, chlorthalidone, Vascular Health and Risk Management 2009:5 413
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decreased cardiovascular complications to an extent similar 
to an ACE inhibitor, lisinopril, or a CCB, amlodipine.39 At 
low doses, thiazide diuretics usually do not cause changes 
in renal function,40 and they can be used when the estimated 
GFR is  30 mL/min. However, diuretics may cause urinary 
electrolyte wasting, and consequently hyponatremia, hypoka-
lemia and/or hypomagnesemia. In addition, diuretic-induced 
volume reduction may activate the renin-angiotensin system, 
limiting their hypotensive action,41,42 and cause pre-renal 
azotemia. Finally, thiazide diuretics may cause metabolic 
adverse effects, including hyperuricemia, hypercholesterol-
emia and glucose intolerance, increasing a patient’s likelikood 
of developing diabetes and worsening glycemic control 
in diabetic patients.43,44 About 50% of the hyperglycemic 
effects of thiazides is thought to be the result of decreased 
insulin release from the pancreatic β-cell, mediated by the 
reduction in serum potassium below 3.5 mEq/L.45 In fact, 
total body potassium stores play a central role in the control 
of insulin secretion,46 probably because ATP-sensitive K+ 
channels couple β-cell metabolism to electrical activity. 
A recent analysis of the Systolic Hypertension in Elderly 
Program (SHEP)47 showed that incidence of new diabetes is 
related to the severity of hypokalemia, even after adjusting 
for baseline glucose and the dose of diuretic. The absolute 
increase in the incidence of diabetes mellitus was much less 
when serum potassium concentration dropped from 5.0 to 
4.5 mEq/L but much higher when serum potassium dropped 
from 4.0 to 3.5 mEq/L. In any case, it has to be noted that 
even when there were no changes in kalemia the incidence of 
diabetes was about double with placebo than with thiazide, 
and that K+ supplementation in SHEP did not prevent new-
onset diabetes. In the recently published Mechanisms for the 
Diabetes Preventing Effect of Candesartan (MEDICA) trial,48 
a multicenter 3-way crossover trial, 26 non-diabetic, obese 
hypertensives underwent 12-week treatment periods with 
candesartan, hydrochlorothiazide (HCTZ) and placebo; after 
12 weeks on thiazides (compared to candesartan), visceral 
and hepatic fat accumulation, higher inflammation markers 
(C-reactive protein, serum amyloid), glycated hemoglobin 
and transaminases were observed; in addition, insulin sensi-
tivity was reduced after HCTZ versus candesartan or placebo, 
independently of changes in kalemia. As a consequence, the 
diabetogenic effects of thiazides are most likely multifacto-
rial, with a clear non-K+ dependent component.49
Therefore, the combination of an ACE inhibitor with a 
diuretic has a strong physiopathological rationale (Table 1); 
it allows improved BP control,50–53 it counterbalances RAS 
activation secondary to diuretic therapy and reduces the 
risk of hyper- or hypokalemia, obtaining at the same time 
synergistic antiproteinuric effects.54 Additionally, high 
sodium intake generally blunts the antiproteinuric effects of 
RAS blockers; the use of thiazide diuretics overcomes this 
blunting effect.55–57 Moreover, the combination of an ACE 
inhibitor with a diuretic is particularly useful in African-
American patients, where monotherapy with conventional 
doses of RAS blocking agents is often unsuccessful or 
marginally successful.58 Finally, ACE inhibitors may at least 
theoretically mitigate the alterations in glucose metabolism 
induced by diuretics.59 Numerous clinical investigations 
have shown that ACE inhibitors can improve insulin action 
on whole-body and skeletal muscle glucose disposal in 
insulin-resistant and hypertensive subjects, through multiple 
mechanisms. For example, the acute administration of 
captopril during a euglycemic glucose clamp caused a 25% 
increase in whole-body insulin sensitivity.60 After the acute 
administration of captopril in type 2 diabetic subjects, a 
decreased daily glucose profile and increased postprandial 
forearm blood flow were also observed.61 Even acute oral 
administration of the ACE inhibitor captopril at lower doses, 
which has no effect on BP, was able to improve peripheral 
insulin-stimulated glucose disappearance in insulin-resistant 
individuals.62 As discussed in an extensive review,63 chronic 
administration of ACE inhibitors is usually associated with 
increased insulin sensitivity.64,65 Large intervention trials 
have provided evidence that ACE inhibitor monotherapy 
may have a positive impact on glucose metabolism. In 
the Heart Outcomes and Prevention Evaluation (HOPE) 
study,66 3.6% of the patients in the ramipril group devel-
oped diabetes, compared with 5.4% in the placebo group 
(p  0.001). In the FACET,29 both fosinopril and amlodipine 
decreased fasting serum glucose and serum insulin in 
patients with type 2 diabetes mellitus and hypertension. In 
the ALLHAT trial,67 only 8.1% of the patients randomized 
to lisinopril developed diabetes, compared with 11.6% in 
the diuretic group. A network meta-analysis68 showed that 
Table 1 Advantages of ACe inhibitor/diuretic combination therapy
improved blood pressure control
Counterbalances renin-angiotensin system activation secondary to 
diuretic therapy
Reduced risk of electrolyte disorders (eg, hyper- or hypokalemia, 
hypomagnesemia)
Synergistic antiproteinuric effects, particularly in the presence of high 
sodium intake
Better therapeutic response in African-American patients
Blunts the adverse metabolic effects induced by the diureticVascular Health and Risk Management 2009:5 414
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hyperglycemia and subsequent diabetes occur more often in 
patients receiving diuretics (or beta-blockers) instead of ACE 
inhibitors (or ARBs). However, only a limited number of 
studies has explored the metabolic effects of ACE inhibitor/
diuretic combination therapy. In 1983, two multicenter tri-
als compared the effects of an ACE inhibitor, captopril, 
combined with a diuretic to the administration of either 
agent alone in mild to moderate hypertensives.69 In addi-
tion to BP, effects on serum potassium, uric acid, glucose, 
and cholesterol were examined. The first study (study A) 
was conducted on 210 hypertensives randomly assigned to 
receive HCTZ 15 mg 3 times daily, captopril 25 mg 3 times 
daily or captopril plus HCTZ for 6 weeks. The second 
study (study B) involved 415 patients randomly assigned to 
receive captopril 25 mg twice daily plus HCTZ 25 mg twice 
daily, captopril 50 mg twice daily plus HCTZ 25 mg 
twice daily, captopril 50 mg twice daily plus placebo, 
HCTZ 25 mg twice daily plus placebo, or placebo alone for 
6 weeks. In both studies, all patients except those receiving 
placebo only had significant BP reductions (p  0.05). In 
both studies, those treated with HCTZ alone had a significant 
(p  0.05) reduction in serum potassium and increases in 
uric acid, glucose and cholesterol when compared to capto-
pril alone, where no significant changes in these parameters 
were observed in the combination arms. In another study,58 
255 essential hypertensive patients were assigned to receive 
HCTZ, captopril, or both. With HCTZ alone, significant 
decreases in serum potassium, increases in uric acid, blood 
glucose, and blood cholesterol were observed (p  0.05). 
With captopril alone, no changes in any of these parameters 
were seen. When captopril was added to HCTZ, attenuation of 
the diuretic effect on potassium and uric acid was significant, 
and the significant changes in blood sugar and cholesterol 
seen with the diuretic alone were prevented. In a small trial,70 
10 hypertensive patients with type 2 diabetes mellitus were 
treated for 8 weeks with enalapril 20 mg/day and then divided 
in 2 groups of 5 patients each for an additional 8 weeks of 
treatment with enalapril alone or in combination with HCTZ; 
no significant difference was observed in any of the metabolic 
characteristics, including insulin sensitivity, between the 
values after 8 weeks of enalapril alone and the final values of 
the enalapril-treated and the enalapril/HCTZ-treated groups. 
In a 12-week multi-center dose-response study in 353 patients 
with essential hypertension,71 combination therapy with 
zofenopril/HCTZ (30/12.5 mg/day or 60/12.5 mg/day) 
was more effective in maintaining continuous 24-hour BP 
control than either agent administered alone; the occurrence 
of treatment-related adverse events was comparable among 
the treatment groups, and the most common adverse events 
were cough and polyuria. Treatment withdrawal occurred in 
only 1.7% of patients. There were no increases in low-density 
lipoprotein cholesterol levels or triglycerides, blood glucose 
or uric acid levels with combination therapy. However, 
concerns about the metabolic effects of ACE inhibitor/
diuretic combination therapy in hypertensive type 2 diabetics 
have been raised by other trials,72,73 even if a recent large 
randomized trial, ADVANCE, did not show any deteriora-
tion in glycemic control in type 2 diabetics randomized to 
an ACE inhibitor, perindopril, plus a thiazide-like diuretic, 
indapamide.74 In any case, while the metabolic effects of 
ACE inhibitor plus diuretic combinations are still a matter 
of debate, available evidence strongly supports the metabolic 
benefits of the ACE inhibitor/CCB combination, particularly 
in patients with prediabetes (glucose intolerance, metabolic 
syndrome or history of gestational diabetes) or diabetes 
mellitus (see below).
Although ACE inhibitors and diuretics have been 
individually used in a large number of trials on cardiovascular 
or renal endpoints, head-to-head comparisons between ACE 
inhibitor/diuretic combinations and other drugs or placebo 
in hypertensive type 2 diabetics are still a rarity.
Cardiovascular endpoints
In the Preterax in Albuminuria Regression (PREMIER) 
trial,75 which enrolled 457 microalbuminuric, hypertensive, 
type 2 diabetics (see below), analysis of serious cardio-
vascular adverse events showed an incidence of 2.5% 
(6 of 244) in the perindopril/indapamide group versus 
6.3% (15 of 237) in the enalapril group (relative risk [RR] 
2.65, 95% confidence interval [CI] 1.03–6.83, p = 0.036). 
Combination therapy allowed a greater SBP (-14.8 mmHg) 
and DBP (-8.8) reduction, as compared to enalapril mono-
therapy (SBP -12.3 mmHg, DBP -7.3 mmHg).
In the Perindopril Protection Against Recurrent Stroke 
Study,76 a total of 6105 patients with a history of stroke or 
transient ischemic attack were randomized to either perindo-
pril with the discretional addition of the diuretic indapamide 
or placebo. 58% of participants received a combination 
therapy, in order to maximize the decrease in BP. The aim of 
the trial was to determine the effects of active treatment on 
major CV events among patients with a history of cerebro-
vascular disease. Of 6105 randomized participants, 761 had 
diabetes at baseline (88% type 2 diabetes),77 with a mean 
SBP of 149 mmHg and a mean DBP of 84 mmHg. 
During the 4 years of follow-up, diabetic patients had a 
35% (95% CI 10–64, p = 0.004) additional risk of stroke. Vascular Health and Risk Management 2009:5 415
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The RR estimates for total major vascular events among 
diabetic participants were 0.54 (95% CI 0.35–0.82) and 1.35 
(95% CI 0.87–2.1) (p homogeneity = 0.003) for patients 
assigned at baseline to receive combination (perindopril 
plus indapamide) and single-drug therapy, respectively. 
Likely, the greater BP reduction produced by combination 
therapy may explain part of the protection against macrovas-
cular events.
The Action in Diabetes and Vascular Disease: preterAx 
and diamicroN-MR Controlled Evaluation (ADVANCE) 
study74 was designed to assess the effects on vascular disease 
of a fixed combination of the ACE inhibitor perindopril 
and the diuretic indapamide. In this study, 11,140 patients 
with type 2 diabetes, at least one additional risk factor and a 
wide range of BP values (mean baseline SBP: 145 mmHg; 
mean baseline DBP: 81 mmHg) were randomized to 
double-blind treatment with either perindopril-indapamide 
(n = 5 569) or placebo (n = 5 571). Primary study outcome 
was a composite of major macrovascular (cardiovascular 
[CV] death, non-fatal myocardial infarction [MI], non-fatal 
stroke) and microvascular (new or worsening nephropathy 
and retinopathy) events. After a mean of 4.3 years of follow-
up, active therapy reduced SBP by 5.6 mmHg and DBP by 
2.2 mmHg, as compared to placebo. 861 patients (15.5%) 
in the perindopril/indapamide group and 938 (16.8%) in the 
placebo group reached the primary outcome (relative risk 
reduction: 9%; 95% CI 0%–17%; p = 0.041). The effects of 
active treatment on major macro- or microvascular outcomes 
were similar (8% vs 9%), though not separately significant. 
The RR of death from CV disease was reduced by 18% 
(p = 0.03) and death from any cause by 14% (p = 0.03). 
There was no evidence of an interaction between the effect 
of treatment and baseline SBP, considered as a continuous 
variable.
Renal endpoints
In an old trial comparing the long-term effects of ACE 
inhibitors and CCBs in the treatment of type 2 diabetes 
associated with hypertension,78 102 patients normo- (n = 44), 
micro- (n = 36) or macroalbuminuric (n = 22) were randomly 
allocated to either nifedipine (n = 52) or enalapril (n = 50). 
Indapamide 2.5 mg/day or furosemide (up to 120 mg/day) 
were added if the BP remained high. At 1 year, 76% of the 
patients in the enalapril arm required the addition of diuretic 
treatment, as compared with only 14% in the nifedipine arm. 
Treatment with enalapril (and diuretic) reduced proteinuria 
significantly more than nifedipine, in all patients and also in 
the micro- and macroalbuminuric groups separately, despite a 
significantly higher BP in the enalapril than in the nifedipine 
arm of the trial (p  0.001).
The Preterax in Albuminuria Regression (PREMIER) 
trial75 was designed as a 12-month, randomized, controlled, 
double-blind, two-parallel group study. 457 patients with 
type 2 diabetes, hypertension and microalbuminuria were 
randomized to either low-dose combination of perindopril 
and indapamide (n = 233) or enalapril monotherapy (n = 224). 
Primary endpoint was the reduction of albumin excretion rate 
(AER). The perindopril/indapamide combination resulted in 
a statistically significant reduction in both BP (∆SBP -3.05 
mmHg, 95% CI -5.6/-0.4, p = 0.012; ∆DBP -1.5 mmHg, 
95% CI: -3/-0.1, p = 0.019) and AER (-42%, 95% CI -50 
to -33%; versus -27%, 95% CI -37/-16% with enalapril). 
Additionally, the greater AER reduction remained significant 
after adjustment for mean BP. Tolerability was comparable 
between therapies, with 47 adverse events in the combina-
tion versus 48 in the enalapril arm; the most frequent ones 
were cough (perindopril/indapamide 3.7%, enapril 2.1%) and 
dizziness (perindopril/indapamide 1.2%, enalapril 2.1%).
In the aforementioned ADVANCE trial, the following 
renal events were taken into account: development of micro- 
or macroalbuminuria, doubling of serum creatinine level to 
a level of at least 200 µmol/L, need for renal replacement 
therapy, or death from renal disease. During the follow-
up period there were 1243 (22.3%) total renal events in 
the perindopril-indapamide group versus 1500 (26.9%) in 
the placebo group, with a relative risk reduction of 21% 
(95 CI 15%–7%, p  0.0001). A nearly significant reduction 
in new or worsening nephropathy was also observed 
(RR reduction: 18%; 95% CI -1 to -32%; p = 0.055). Of 
particular importance in the setting of primary prevention of 
diabetic nephropathy (ie, normoalbuminuric patients), there 
was a significant reduction in the onset of microalbuminuria 
(RR reduction: 21%; 95% CI 14%–27%; p  0.0001). Thus, 
over 5 years, 1 patient in every 20 assigned active treatment 
would have avoided 1 renal event, mainly the development of 
microalbuminuria. However, the most important factors that 
prevent the progression of renal damage in diabetes mellitus 
are the improvement of blood glucose control and a tighter 
BP control. In the ADVANCE trial, a reduction of  5.6 mmHg 
in SBP was observed among patients randomized to receive 
perindopril and indapamide, as compared with those assigned 
to receive placebo. Additionally, the same 11,140 patients 
were also randomized to undergo either a strategy of intensive 
blood glucose control (target glycated hemoglobin 6.5%) or 
a strategy of standard glucose control,79 and intensive control 
reduced the incidence of combined major- or microvascular Vascular Health and Risk Management 2009:5 416
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events by 10% (hazard ratio [HR] 0.9, 95% CI 0.82–0.98, 
p = 0.01) and the incidence of nephropathy by 21% (HR 
0.79, 95% CI 0.66–0.93, p = 0.006). As a consequence, the 
specific role of the fixed-dose combination of perindopril 
and indapamide in reducing the risk of new or worsening 
nephropathy is difficult to establish.
ACE inhibitor plus CCB
Rationale of the combination
The effects of RAS blockade in patients with type 2 diabetes 
and hypertension have already been described. Contrasting 
results have been reported on the CV effects of CCBs in 
diabetic hypertensive patients. In the Swedish Trial in Old 
Patients with hypertension-2 (STOP-2),80 719 diabetic and 
hypertensive patients aged 70 to 84 years were assigned to 
calcium antagonists (felodipine or isradipine, N = 231), ACE 
inhibitors (enalapril or lisinopril, N = 235) or conventional 
treatment (diuretics or beta-blockers, N = 253). The 
BP-lowering effects were similar in the three treatment 
groups. Treatment effects did not differ significantly for 
frequency of the primary endpoint (CV mortality). On the 
contrary, the ABCD trial, comparing enalapril and nisol-
dipine in 470 patient with non-insulin dependent diabetes 
and hypertension, was stopped prematurely because of a 
significantly higher incidence of MI among those random-
ized to CCB.30 In the Irbesartan versus amlodipine Diabetic 
Nephropathy Trial,35 1715 hypertensive patients with type 2 
diabetic nephropathy were randomized to either irbesartan 
or amlodipine or placebo. After 2.6 years of follow-up, the 
treatment with CCB, compared with ARB, provided the 
same incidence of major CV events, CV death, and total 
mortality. Finally, the FACET trial,29 which enrolled 380 
hypertensive type 2 diabetics randomly assigned to open-
label fosinopril or amlodipine and followed up for 3.5 years, 
found a higher incidence of the combined outcome of acute 
MI, stroke, or hospitalized angina among patients assigned to 
amlodipine. However, those trials (STOP-2, ABCD, IDNT 
and FACET) are head-to-head comparisons between CCBs 
and agents blocking the RAS, and a few of them may suffer 
from a number of methodological flaws.81 In fact, CCBs 
compared with conventional therapy are able to reduce the 
risk of non-fatal stroke by 25%,82 thanks to their antiath-
erogenic83–85 and antithrombotic86,87 properties. On the other 
hand, CCBs (mainly dihydropyridinic) could increase the 
risk of MI,82 through an increased adrenergic stimulation. 
Finally, dihydropyrinidic CCBs may commonly cause ankle 
edema, through three different mechanisms: arteriolar vaso-
dilation, impairment of the local vascular autoregulation 
of blood flow and impaired protection against hydrostatic 
load.88 Differences in sympathetic overactivation after arterial 
vasodilatation may lead to different ankle edema rates. So, 
dihydropyridinic CCBs that activate the sympathetic nervous 
system to a lesser extent (ie, manidipine)89 may have a more 
favorable adverse event profile.
CCBs differ in their effect on glomerular hemodynamics and 
urinary albumin excretion.90 Conventional dihydropyridinic 
CCBs may cause vasodilation of afferent renal arterioles with 
little change in the efferent arteriole diameter, and conse-
quently increase intraglomerular pressure and proteinuria; 
newer dihydropyrinidic CCBs (ie, manidipine, benidipine) are 
believed to induce vasodilatation not only in the glomerular 
afferent arteriole, but also in the efferent arteriole, resulting 
in a reduced proteinuria.91–93 Non-dihydropyridinic CCBs (ie, 
verapamil) offer a mild protective effect on proteinuria in 
diabetic nephropathy, beyond their antihypertensive action.94 
Concerning the renal effects of CCBs in patients with type 
2 diabetes and hypertension, it is important to note that all 
trials directly comparing CCBs and RAS blocking agents 
(ACE inhibitors or ARBs) showed no difference in the 
rate of change of GFR.81 So, even if albuminuria is usually 
more markedly reduced by ACE inhibitors or ARBs than by 
CCBs, this does not translate into a greater renoprotection, 
as expressed by the slope of GFR reduction, but only into 
greater CV protection.
In light of the above, the combination of an ACE inhibitor 
with a CCB may offer several advantages (Table 2). First, it 
obviously provides a consistent and significant addictive effect 
on BP reduction,95–103 without affecting lipid and carbohydrate 
metabolism.104
Secondly, ACE inhibitors plus CCBs may have favorable 
metabolic effects. In hypertensive patients with impaired glu-
cose tolerance, the combination of trandolapril with verapamil 
Table 2 Advantages of ACe inhibitor-calcium channel blocker 
combination therapy
improved blood pressure control
Favorable metabolic effects
Counterbalances the reflex increase in sympathetic nervous activity 
induced by calcium channel blockers
Reduced vasodilatory edema
Diuretic and natriuretic effects of calcium channel blockers
Synergistic reduction of proteinuria and the rate of decline in glomerular 
filtration rate
increased NO production and decreased cytokine production
improved fybrinolitic balance
improved arterial distensibilityVascular Health and Risk Management 2009:5 417
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reduced the risk of new-onset diabetes, as compared with 
an angiotensin receptor blocker plus a thiazide diuretic;105 
in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood 
Pressure Lowering Arm (ASCOT-BPLA),106 an ACE 
inhibitor/CCB combination lowered the risk of new-onset 
diabetes by 30%; in addition, type 2 diabetic patients treated 
with trandolapril plus verapamil had a better glycemic control 
than those treated with an ACE inhibitor as monotherapy, 
unrelated to their antihypertensive effect.107 The metabolic 
results are even better when new dihydropyridines are 
combined with ACE inhibitors. A recent trial showed a 
remarkable 59% increase in insulin sensitivity with the 
delapril/manidipine fixed combination in obese hypertensives 
after 24 weeks, while olmesartan/thiazide combination was 
ineffective.108 Two mechanisms have been proposed for the 
reduction of insulin resistance observed with CCBs: first, 
these drugs produce vasodilation and enhance blood flow to 
skeletal muscle with consequent increased delivery of insulin 
and glucose and enhanced non-oxidative pathways of glucose 
utilization; in addition, CCBs also improve insulin sensitivity 
at the cellular level by decreasing the cytosolic-free calcium 
concentrations.109,110
Thirdly, systemic vasodilation induced by CCBs 
(especially dihydropyridines) signals a reflex increase in 
sympathetic nervous activity, which thereby increases heart 
rate and enhances renal renin excretion,111 reducing the 
hypotensive properties of the drug; these effects may be coun-
terbalanced by RAS blockade. Fourthly, vasodilatory edema 
that may occur with CCBs is often diminished when an ACE 
inhibitor is added to the antihypertensive regimen.112 Fifthly, 
the diuretic and natriuretic effect of CCBs complements ACE 
inhibitor therapy much as diuretic therapy does, but makes 
it possible to control BP without using a diuretic when that 
is desirable;113 additionally, ACE inhibitors blunt the stimu-
lation of the renin-angiotensin-aldosterone axis that may 
result from this diuretic effect. Sixthly, in hypertensive type 
2 diabetics, the combination of an ACE inhibitor and a CCB 
may synergistically reduce proteinuria and the rate of decline 
in GFR.114 Finally, ACE inhibitors and CCBs stimulate nitric 
oxide (NO) production through kinin-dependent mechanisms 
and significantly decrease levels of all inflammatory markers 
(tumor necrosis factor-α, interleukin-6, nuclear factor-κB); 
preclinical evidence suggests that combination therapy has 
additive effects.115–117 The mechanisms of vascular damage 
in diabetic patients are very complex, but excess production 
of reactive oxygen species, endothelial dysfunction and 
decreased NO bioavailability play key pathogenic roles. 
In such patients, the neurohormonal imbalance between 
angiotensin II and NO associated with endothelial dysfunction 
may also contribute to inflammation and cardiac remodeling 
after myocardial ischemia. So, ACE inhibitor/CCB combina-
tion therapy may have beneficial effects in the management of 
cardiac ischemia and left ventricular hypertrophy, by limiting 
inflammation and restoring neurohormonal balance,118 as well 
as on fibrinolytic balance119 and arterial distensibility.120,121
A number of hypertension trials and trials on CV or renal 
endpoints have compared ACE inhibitor/CCB combination 
therapy and other drugs/placebo in patients with type 2 
diabetes and hypertension.
Hypertension trials
In 1991,104 in order to assess the efficacy and tolerability 
of a diuretic-free antihypertensive therapy with an ACE 
inhibitor and a CCB, 47 type 2 diabetic hypertensives 
randomly received verapamil or enalapril alone and, if BP 
remained elevated, both agents combined, over a 30-week 
period. After 10 weeks of monotherapy, 30 patients obtained 
a DBP lower than 90 mmHg. In the remaining 17 patients, 
verapamil/enalapril combination therapy decreased BP from 
170 ± 4/104 ± 2 to 152 ± 4/90 ± 2 mmHg (p  0.001). Fasting 
plasma glucose, glycosylated hemoglobin, serum fructos-
amine, total lipids, high-density and low-density lipoprotein 
cholesterol, apolipoproteins A-I and B, creatinine, and urinary 
albumin-creatinine ratio were not significantly modified, 
demonstrating that BP can be effectively decreased without 
adversely affecting carbohydrate and lipid metabolism.
A subsequent small crossover trial in 38 patients with 
type 2 diabetes and hypertension,119 assigned to benazepril 
10 mg/day, amlodipine 5 mg/day or their combination, 
showed that combination therapy produced a significantly 
greater reduction in both SBP and DBP than either drug 
alone, with a mean decrease in BP of -28.3/-20.5 mmHg 
(p  0.001 versus placebo; p  0.01 versus benazepril or 
amlodipine monotherapies). The benazepril/amlodipine 
combination improved fybrinolytic balance more than the 
single drugs, due to both the decrease in plasma PAI-1 
activity and the increase in t-PA activity. These effects 
may be of particular importance in diabetic hypertensive 
patients, who have an impaired fibrinolytic activity, which 
may contribute to the increased risk of atherosclerosis and 
its clinical complications.
In the Study of Hypertension and the Efficacy of Lotrel 
in Diabetes (SHIELD) trial,122 a randomized, double-blind 
study, 214 patients with hypertension and type 2 diabetes were 
assigned to amlodipine/benazepril (5/10 mg) combination 
therapy or conventional treatment (enalapril 10 mg/day). Vascular Health and Risk Management 2009:5 418
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If target BP (130/85 mmHg) was not achieved, study drugs 
were titrated to 10/20 mg/day or 20 mg/day, respectively. 
HCTZ was added if target BP was still not reached. Time 
from baseline to achieve BP  130/85 mmHg was shorter in 
the combination arm (5.3 ± 3.1 weeks versus 6.4 ± 3.8 weeks, 
p = 0.001). At 3 months, 63% of patients in the combination 
group achieved treatment goal, versus 37% in the conven-
tional treatment group (p = 0.002).
A controlled clinical trial123 investigated the CCB 
lercanidipine versus HCTZ as add-on to enalapril mono-
therapy in diabetic patients (type 1 or 2) with uncontrolled 
hypertension. 174 subjects were included in a 2-week placebo 
run-in, followed by 4 weeks on enalapril 20 mg/day. There-
fore, 135 non-responders (DBP  90 mmHg) were random-
ized to either lercanidipine 10 mg/day or HCTZ 12.5 mg/day. 
Both add-on therapies reduced DBP to a greater extent than 
enalapril monotherapy; target BP (130/85 mmHg) was 
achieved in 30.4% of patients on lercanidipine add-on and 
in 23.2% of subjects on HCTZ add-on, but the differences 
between the responder rates in the two treatment groups did 
not reach statistical significance (p  0.05). Both combina-
tions were well tolerated.
The Amlodipine in Diabetes (ANDI) trial,124 a randomized 
parallel-group trial, investigated BP lowering in 374 patients 
with type 2 diabetes and hypertension. Subjects not reaching 
BP goals (130/80 mmHg) after a 4-week open-label treat-
ment with quinapril 20 mg/day (n = 374) were assigned to 
either quinapril 40 mg/day (n = 167) or quinapril 20 mg/day 
plus amlodipine 5 mg/day(n = 62). After 6 weeks of treatment, 
patients receiving combination therapy had significantly 
greater reductions in SBP (9.9 ± 1.0 mmHg vs 4.3 ± 1.1 mmHg, 
p  0.001) and DBP (6.5 ± 0.6 mmHg vs 2.7 ± 0.6 mmHg, 
p  0.001), as compared to quinapril monotherapy. Both treat-
ments were well tolerated, and showed a clinically neutral 
effect on high-sensitivity C-reactive protein.
The MORE trial125 investigated the efficacy of the fixed-
dose combination of a CCB (manidipine 10 mg/day) and 
an ACE inhibitor (delapril 30 mg/day), compared with a 
combination of an ARB (losartan 50 mg/day) and a diuretic 
(HCTZ 12.5 mg/day), in 314 patients with hypertension 
and controlled type 2 diabetes (HbA1c  7.5%). All patients 
underwent ambulatory BP monitoring at baseline and at 
the end of treatment. After 12 weeks, mean decreases in 
24-hour SBP were -9.3 mmHg in the manidine/delapril arm 
(n = 80) and -10.7 mmHg in the losartan/HCTZ arm (n = 94), 
respectively. The mean treatment difference was -1.4 mmHg 
(95% CI -4.5/-1.8), demonstrating the non-inferiority of 
the manidipine/delapril combination. A lower percentage 
of patients with increased HBA1c or requiring additional 
oral antidiabetic therapy was also observed in the CCB/ACE 
group. Both treatments were well tolerated and displayed 
comparable safety profiles.
Cardiovascular endpoints
Few large randomized clinical trials have evaluated the 
effects of a combination regimen (ACE inhibitor + CCB) on 
major CV outcomes in patients with both diabetes (mostly 
type 2) and hypertension.
In the aforementioned FACET trial,29 380 type 2 diabetic 
hypertensives were assigned to open-label therapy with either 
fosinopril (n = 189) or amlodipine (n = 191). The goal BP was 
defined as SBP  140 mmHg and DBP  90 mmHg. How-
ever, if BP was not controlled with monotherapy, the other 
study drug was added at full dose. Therefore, amlodipine was 
added in 30.7% of the fosinopril group patients (58/189), 
and fosinopril was added in 26.2% of the amlodipine group 
patients. The proportion of patients reaching the combined 
end point of stroke, acute MI or hospitalized angina was 
significantly lower in the fosinopril group compared with 
amlodipine (HR 0.49, 95% CI 0.26–0.95, p = 0.03). In 
crude analyses according to postrandomization treatment, 
the patients who received fosinopril only (n = 131), amlo-
dipine only (n = 141) and the combination of fosinopril 
plus amlodipine (n = 108) experienced 10, 27, and 4 major 
vascular events, respectively. In the same three groups, the 
number of patients experiencing acute MI was 7, 13, and 3, 
respectively; the number of patients with hospitalized angina 
was 0, 4 and 0; and the number of patients who experienced 
stroke was 3, 10 and 1, respectively. Compared with amlo-
dipine alone, the combination treatment with fosinopril and 
amlodipine decreased the risk of major vascular events more 
than fosinopril only (HR 0.17, 95% CI 0.06–0.5, p = 0.001 
versus HR 0.37, 95% CI 0.18–0.77, p = 0.008, respectively). 
Therefore, combination therapy with ACE inhibitor and CCB 
scored better than monotherapy, but this important finding 
was not emphasized by the authors.81
In the Hypertension Optimal Treatment (HOT) trial,126 18,790 
hypertensive patients (DBP between 100 and 115 mmHg) were 
randomly assigned to different target diastolic BP:  90 mmHg 
(n = 6 264), 85 mmHg (n = 6264) or 80 mmHg (n = 6262). 
A CCB (felodipine) was given as baseline therapy, with 
the possible addition of other agents, according to a 5-step 
regimen. ACE inhibitors were added at step two, and most 
patients received an ACE inhibitor/CCB combination therapy. 
In the diabetic cohort of the trial (n = 1501), a decline in the 
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group (p = 0.005). In the group randomized to 80 mmHg 
the risk of major CV events was halved in comparison with 
that of the target group 90 mmHg. When silent MI was 
included, this change was attenuated but remained significant. 
The approximate halving of the risk was also observed for 
all MI, although not statistically significant. All stroke also 
showed a declining rate with lower target BP groups, with a 
risk reduction of about 30% in the 80 mmHg target group 
vs 90 mmHg target group. Cardiovascular mortality was 
also significantly lower in the 80 mmHg target group than 
in each of the other target groups.
In the diabetic subgroup of the Systolic Hypertension in 
Europe Trial (492/4695 patients),127 subjects with diabetes 
and systolic hypertension were randomly assigned to either 
active treatment or placebo. Active treatment consisted of 
a CCB (nitrendipine 10 to 40 mg/day), with the possible 
addition or substitution of enalapril (5 to 20 mg/day) or 
HCTZ (12.5 to 25 mg/day) or both, titrated to reduce SBP 
by at least 20 mmHg and to less than 150 mmHg. Again, the 
second step was an ACE inhibitor, and most patients received 
an ACE inhibitor plus CCB combination. At 2 years, active 
treatment reduced overall mortality by 55% (from 45.1 
deaths per 1000 patients to 26.4 deaths per 1000 patients), 
CV mortality by 76%, all CV events combined by 69%, fatal 
and non-fatal strokes by 73% and all cardiac events combined 
by 63%. Reductions in overall mortality, CV mortality and 
all CV events were significantly larger among the diabetic 
patients than among the nondiabetics (p = 0.04, p = 0.02, and 
p = 0.01, respectively).
The International Verapamil-Trandolapril Study 
(INVEST),128 a prospective, randomized, open-label, 
blinded endpoint (PROBE) trial, enrolled 22,576 patients 
with hypertension and CHD, randomly assigned to a non-
dihydropyridine CCB (verapamil SR) or a beta blocker-
based (atenolol) regimen, and followed up for a mean 
duration of 2.7 years. In the diabetic cohort of the trial,129 
6,400 patients were randomized to 240 mg/day of verapamil 
SR or 50 mg/day of atenolol, titrated to maximal doses to 
achieve a target BP of 130/85 mmHg. If BP goal was not 
achieved, trandolapril and HCTZ were recommended as 
primary and secondary add-on agents in the verapamil SR 
group, and the sequence was reversed in the atenolol group. 
At 24 months, the majority of participants required add-on 
therapy, with differences in use of trandolapril and HCTZ 
by strategy. In the verapamil SR group, 72.1% of patients 
were taking trandolapril and 51.2% HCTZ, versus 64.1% 
and 62.8% of patients in the atenolol group, respectively. 
Risk for primary (a composite of death, non-fatal MI or 
non-fatal stroke) and secondary outcomes (death, non-fatal 
MI, non-fatal stroke, BP control, CV hospitalizations, and 
CV death) did not differ by strategy, as well as BP control. 
Finally, an on-treatment analysis of randomized drugs, using 
atenolol 50 mg/day as a reference group, indicated a trend 
for reduced risk of the primary outcome with the addition of 
2 mg/day of trandolapril to the verapamil-SR based strategy or 
of 12.5 mg/day of HCTZ to the atenolol-based strategy. This 
trial suggested that a combination therapy was more effective 
for reducing adverse outcomes in diabetic hypertensives, and 
that an ACE inhibitor/CCB combination could be used as an 
alternative to a beta-blocker based strategy in patients with 
concomitant CAD.
In the Bergamo Nephrologic Diabetes Complication 
(BENEDICT) trial,130 enrolling 1204 normoalbuminuric 
patients with type 2 diabetes and hypertension, randomized 
to trandolapril, verapamil, verapamil plus trandolapril or pla-
cebo (see below), the incidence of non-fatal CV events was 
similar in the four treatment groups (3.7% in the combination 
group, 4.0% in the trandolapril group, 4.3% in the verapamil 
group, and 4.0% in the placebo group). One subject receiving 
trandolapril, 1 receiving verapamil, and 3 receiving placebo 
died from a CV event. No fatal CV events occurred in the 
group receiving trandolapril plus verapamil.
The Anglo-Scandinavian Cardiac Outcomes Trial-Blood 
Pressure Lowering Arm (ASCOT-BPLA)106 was designed to 
compare the effect on non-fatal MI and fatal CHD of two 
combination strategies, atenolol plus bendroflumethiazide 
versus amlodipine plus perindopril, in more than 19,000 
hypertensive patients with no prior history of CHD. The study 
population was required to have at least three additional risk 
factors for CV disease: type 2 diabetes, peripheral arterial 
disease, previous stroke or transient ischemic attack, microal-
buminuria or proteinuria, smoking and so forth. In the diabetic 
cohort of the trial,131 5137 patients were randomized to the 
atenolol-based regimen (n = 2 572) or to the amlodipine-
based regimen (n = 2 565). A majority of patients received 
combination treatment with either amlodipine and perindopril 
or atenolol and thiazide, respectively. The mean SBP and 
DBP throughout the trial were 3.0 and 1.9 mmHg lower in 
the amlodipine/perindopril arm. In the latter, a significantly 
lower incidence of total CV events was observed, compared 
with the atenolol/HCTZ regimen (HR 0.86, 95% CI 
0.76–0.98, p = 0.026). Fatal and non-fatal strokes were 25% 
lower (p = 0.017), peripheral arterial disease 48% lower 
(p = 0.004) and coronary revascularization procedures 57% 
lower (p  0.001) in the amlodipine/perindopril group. 
However, non-fatal MI and fatal CHD, the primary endpoint Vascular Health and Risk Management 2009:5 420
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in ASCOT, were reduced by a non-significant 8% (HR 0.92, 
95% CI 0.74–1.15, p = 0.46).
The recently published Avoiding Cardiovascular events 
through COMbination therapy in Patients Living with 
Systolic Hypertension (ACCOMPLISH) trial,132 which 
included a large population of diabetic patients (see below), 
indicates that the combination of an ACE inhibitor and a 
CCB was superior to the combination of an ACE inhibitor 
and a diuretic in reducing CV endpoints.
Renal endpoints
In a randomized, double-blind, parallel group designed 
trial,133 37 patients with type 2 diabetes, hypertension and 
urinary protein excretion of 300 mg/day were assigned 
to verapamil (a non-dihydropyridinic CCB), trandolapril 
or trandolapril + verapamil. Primary endpoint was a 25% 
greater reduction in urinary protein excretion (detected using 
24-hour urine determinations) in the combination group as 
compared to either trandolapril or verapamil alone. Dur-
ing the trial, there was a 3 to 4 mmHg lower mean arterial 
pressure in the combination group versus monotherapy 
groups. The combination of trandolapril and verapamil 
produced and sustained a greater reduction in proteinuria 
(from 1403 to 592 mg/day) compared to higher doses of 
either verapamil (from 1349 to 985 mg/day) or trandolapril 
(from 1274 to 840 mg/day), independently of BP reduction 
(p  0.05).
In a subsequent, larger trial,134 309 hypertensive patients 
with type 2 diabetes and microalbuminuria were randomized 
to the dihydropyridinic CCB amlodipine (5 to 15 mg/day), 
the ACE inhibitor fosinopril (10 to 30 mg/day), or both 
drugs. During the 4 years of follow-up, combination therapy 
was more effective in reducing BP than either drug alone, 
without affecting glucose homeostasis. All three treatments 
resulted in a significant decrease in urinary albumin excre-
tion (UAE), but this effect became evident earlier and was 
more pronounced in the fosinopril than in the amlodipine 
arm. Again, combination therapy provided a greater antial-
buminuric effect than the single drugs. In addition, a greater 
percentage of patients in the combination group were non-
microalbuminuric at 4 years than in amlodipine or fosinopril 
groups (67%, 33% and 46%, respectively).
In a 12-week, double-blind SHIELD substudy,121 
20 patients with hypertension, type 2 diabetes and microalbu-
minuria were randomized to either a fixed-dose combination 
of amlodipine and benazapril or to enalapril monotherapy. 
At week 12, subjects in both the combination and the 
enalapril group experienced similar reductions from baseline 
in urinary microalbumin excretion, from 124 ± 91 µg/mg 
to 36 ± 14 µg/mg creatinine and from 102 ± 58 µg/mg to 
27 ± 23 µg/mg creatinine, respectively (p  0.01 for both 
groups). Patients in both treatment groups demonstrated 
similar reductions in BP.
In the specific setting of primary prevention of diabetic 
nephropathy, the Bergamo Nephrologic Diabetes Complica-
tion Trial (BENEDICT)130 was designed to assess whether 
ACE inhibitors and non-dihydropyridine CCBs, alone or in 
combination, are able to prevent microalbuminuria in patients 
with type 2 diabetes, hypertension and normal urinary 
albumin excretion. 1204 normoalbuminuric patients were 
randomized to trandolapril (n = 301), verapamil (n = 303), 
verapamil plus trandolapril (n = 300) or placebo (n = 300). 
Primary endpoint was the development of persistent micro-
albuminuria (overnight AER  20 µg/min at two consecu-
tive visits). Target BP was 120/80 mmHg. As compared 
with placebo, trandolapril plus verapamil and trandolapril 
alone decreased the incidence of microalbuminuria to a 
similar extent. In particular, persistent microalbuminuria 
developed in 5.7% of patients receiving combination 
therapy, as compared with 10% of the subjects receiving 
placebo. In addition, the effects of trandolapril/verapamil 
and trandolapril in preventing microalbuminuria exceeded 
expectations based on BP reduction per se. On the other 
hand, verapamil alone did not significantly delay the onset 
of microalbuminuria.
In the Add-on manidipine versus amlodipine in 
diabetic patients with hypertension and microalbuminuria 
(AMANDHA) trial,135 91 diabetic patients with uncon-
trolled hypertension and microalbuminuria despite full-dose 
treatment with a renin-angiotensin system blocker were 
randomized to either manidipine 20 mg/day (n = 61) or 
amlodipine 10 mg/day (n = 30) in a 2:1 ratio. After 6 months 
of treatment, patients were monitored for microalbumin-
uria for additional 18 months. Urinary albumin excretion 
was reduced by 65.5% with manidipine versus 20% with 
amlodipine at 6 months (p  0.01), and by 62.7 versus 
16.6% (p  0.01) at 24 months, confirming the peculiar 
effects on glomerular hemodynamics of the latest generation 
of dihydropyridines.
In conclusion, even if there is sound scientific evidence 
suggesting the efficacy of ACE inhibitors plus CCBs in 
reducing proteinuria, the individual role of the two drug 
classes is still a matter of debate; at least in the case of older 
dihydropyridines, most of the antiproteinuric effects could be 
explained by ACE inhibition alone and/or by the additional 
BP reduction obtained by combination therapy. In any case, Vascular Health and Risk Management 2009:5 421
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combination therapy with ACE inhibitors and CCBs may 
reduce the slope of GFR reduction.114
Other ACE inhibitor combinations
ACe inhibitor plus angiotensin receptor 
blocker
The RAS has evolved to play an integral role in the 
preservation of hemodynamic stability in human beings, by 
regulating extracellular fluid volume, sodium balance, and 
CV function through direct and indirect effects on multiple 
organ systems.136 Activation of the renin-angiotensin axis 
produces the biologically active peptide angiotensin II, which 
has several structural and hemodynamic effects, including 
stimulation of the sympathetic nervous system, vasocon-
striction, increased aldosterone release and sodium reten-
tion, cardiac remodeling, smooth muscle cells growth and 
proliferation, vascular inflammation, generation of reactive 
oxygen species, endothelial dysfunction, renal fibrosis and so 
forth. ACE inhibitors and ARBs work at different steps of the 
RAS. Although ACE inhibitors are able to reduce angiotensin 
II formation, non-ACE dependent pathways have also been 
identified.137 On the other hand, ARBs antagonize the binding 
of angiotensin II to the AT1 receptor, which mediates most of 
the undesirable effects associated with angiotensin II. Each 
of these drug classes has been shown to be effective in the 
treatment of congestive heart failure, proteinuric chronic 
kidney disease (diabetic or not) and high-CV risk patients. 
For example, the RESOLVD pilot study138 demonstrated 
that combining enalapril with candesartan provides superior 
suppression of left-ventricular remodeling and RAS neuro-
hormones as opposed to either therapy alone. The individual 
success of ACE inhibitors and ARBs has fueled the theory 
that combination therapy should provide additional CV and 
renal protection. The foundation of this premise, although 
biologically plausible, has yet to be proven in a compelling 
enough fashion to support the everyday use of these two drug 
classes in combination. To date, no long-term clinical trials 
have assessed mortality and morbidity with ACE inhibitor/
ARB combination therapy in a population consisting exclu-
sively of type 2 diabetic hypertensives. In the VALsartan In 
Acute myocardial iNfarcTion trial,139 14,703 patients (55.3% 
hypertensives) with acute MI complicated by heart failure or 
left ventricular systolic dysfunction or both were randomized 
to captopril (n = 4909), valsartan (n = 4909) or combination 
therapy (n = 4885). In the latter arm, there were 1146 (23.5%) 
diabetic patients (mostly type 2 diabetics, over 70% hyperten-
sives).140 In these subjects, the combination regimen did not 
reduce total mortality (p = 0.7) or the combined CV endpoint 
(p = 0.85), as compared with captopril monotherapy, despite 
additional lowering of BP and a clear increase in the rate of 
intolerance to treatment. The Ongoing Telmisartan Alone 
and in Combination with Ramipril Global Endpoint Trial 
(ONTARGET)141 enrolled 25 620 patients at high CV risk, 
randomized to ramipril (n = 8576), telmisartan (n = 8542) 
or both (n = 8502). 3220 diabetic patients (mostly type 2 
diabetics with hypertension) received the combination of 
the two drugs. Again, combination therapy did not offer an 
additional reduction in the primary outcome (death from 
CV causes, MI, stroke, or hospitalization for heart failure; 
p = 0.15), compared with ramipril, but significantly increased 
the risk of hypotension, syncope, hyperkalemia and renal 
dysfunction. Similarly, no benefit of combination therapy 
on the primary renal outcome (dialysis, doubling of serum 
creatinine, and death) was seen in participants with diabetic 
nephropathy;142 in the ONTARGET trial, the only benefit 
provided by dual RAS blockade was a greater reduction in 
urinary albumin excretion. This finding is consistent with 
a recent meta-analysis investigating combination therapy 
with ACE inhibitors and ARBs for diabetic nephropathy143, 
wherein the combination regimen lowered 24-hour proteinuria 
to a greater extent than either drug as monotherapy, even if 
the few long-term studies included (12 months)144,145 had not 
demonstrated any benefit.
As a consequence, concerns about dual-agent blockade 
of the RAS have been raised, particularly about the 
potential increase in the incidence of hyperkalemia and 
decrease in the GFR, even in the presence of normal renal 
arteries (late-onset renal failure from angiotensin blockade, 
LORFFAB).146,147
ACe inhibitor plus aliskiren
Aliskiren is a low-molecular-weight hydrophilic non-peptide, 
which exerts a potent and specific competitive inhibition on 
renin, the initial and rate-limiting step of the RAS, reducing 
angiotensin I generation from angiotensinogen.148 A reactive 
increase in the activity of the renin occurs when either ACE 
inhibitors or ARBs are used for long periods. Renin exerts 
additional actions through a renin receptor, leading to the 
production of angiotensin and aldosterone. Therefore, the 
prospect of dual blockade of the RAS with aliskiren and an 
ACE inhibitor has appeared promising. A phase 3 clinical 
trial randomized 837 patients with diabetes (mostly type 2 
diabetics) and hypertension to aliskiren 150 mg/day alone, 
ramipril 5 mg/day alone or a combination of aliskiren 
150 mg/day and ramipril 5 mg/day.149 After 4 weeks, the Vascular Health and Risk Management 2009:5 422
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dose in each arm was doubled for an additional 4 weeks. 
At 8 weeks, combination therapy was significantly more 
effective in reducing mean sitting SBP compared with either 
monotherapy (p  0.005), with an additional BP reduction 
of 4.6/2.1 mmHg over ramipril monotherapy. Treatments 
were well tolerated, with adverse events occurring in 
33.8%, 32.3% and 30% of patients on ramipril, aliskiren, or 
aliskiren/ramipril, respectively. Most adverse events were 
mild or moderate. A substudy in 173 patients who underwent 
24-hour BP monitoring at baseline and at the end of the 
trial150 showed that adding aliskiren to ramipril improves 
24-hour BP control compared with monotherapy in patients 
with diabetes and hypertension, with a greater reduction in 
the early morning BP surge (21–24 hours post dose), which 
is associated with an increased CV risk.
ACe inhibitor plus α-adrenergic blocker
In a small crossover trial,151 76 patients with type 2 
diabetes, hypertension and albuminuria were randomized 
to receive the ACE inhibitor cilazapril (2.5–10 mg/day), the 
α-adrenergic blocker doxazosin (2–8 mg/day) or both drugs 
at half doses. Patients of the first two groups received a 
single agent for 4 months, the drugs were then crossed for an 
additional 4 months followed by the addition of HCTZ for 
a final 4-month period. Patients of the cilazapril/doxazosin 
group received both drugs for 4 months, then HCTZ was 
added for an additional 4 months. All three initial regimens 
resulted in significant decline in both SBP and DBP values 
(p  0.001). The combination of cilazapril with doxazosin 
had a significant greater antialbuminuric effect: albuminuria 
decreased from 365 ± 115 to 162 ± 105 mg/24 hours, an 
RR of 56% (95% CI 16%–88%; p = 0.001), as compared 
with 350 ± 105 down to 205 ± 96 mg/24 hours in the 
cilazapril group and with 373 ± 121 down to 322 ± 107 
mg/24 hours in the doxazosin group. In the combination 
arm, the addition of HCTZ was followed by a further 
decline in albuminuria.
Which is the “best” ACE inhibitor 
combination in hypertensive 
patients with type 2 diabetes? 
Update after the GUARD 
and ACCOMPLISH trials
Two recently published trials, GUARD and ACCOMPLISH, 
may help to shed a new light on this area. They are the first 
clinical studies specifically designed to directly compare initial 
combination therapy of either ACE inhibitor and diuretic 
or ACE inhibitor and CCB. In the Gauging Albuminuria 
Reduction with Lotrel in Diabetic Patients with Hypertension 
(GUARD) trial,114 332 hypertensive, albuminuric type 
2 diabetics were assigned to benazepril/amlodipine or 
benazepril/HCTZ. After 1 year of treatment, both combina-
tions significantly reduced the urinary albumin to creatinine 
ratio and the sitting BP. However, while BP was reduced more 
by the combination ACE inhibitor/CCB, initial treatment 
with benazepril and HCTZ resulted in a greater reduction in 
albuminuria, compared with benazepril plus amlodipine. The 
reasons for this difference could be multiple. First, conven-
tional dihydropyridinic CCBs, such as amlodipine, may cause 
vasodilation of afferent renal arterioles with minor changes 
in the efferent arteriole diameter, with a consequent increase 
in intraglomerular pressure and proteinuria. Therefore, the 
observations of the GUARD cannot be extended to other 
dihydropyridinic (ie, manidipine) or non-dihydropyridinic 
CCBs, as clearly showed by the recently published 
AMANDHA trial.135 Other possible explanations suggested 
by the authors of the trial include greater reduction in eGFR 
in the diuretic group as well as differences in preexisting 
volume status. Finally, high sodium intake may blunt the 
antiproteinuric effects of ACE inhibitors; in such patients, 
the use of thiazide diuretics may overcome this blunting 
effect. However, another recently published trial in hyper-
tensive patients with type 2 diabetes152 showed that adding 
manidipine on top of RAS blocker, candesartan, reduced the 
urinary albumin excretion by 53%, while thiazide diuretic 
add-on was ineffective. Altough obtained with a combination 
therapy based on an angiotensin receptor blocker instead of 
an ACE inhibitor, these results are in sharp contrast with the 
discussed GUARD trial.
Interestingly, rates of progression to overt diabetic 
nephropathy by the end of the GUARD trial were similar 
between the benazepril/amlodipine and the benazepril/
hydrochlorotiazide group (4.6% vs 4.0%, p = 0.79). More 
importantly, the mean decrease in the estimated GFR (eGFR) 
over the 52-week period was less in the benazepril/amlodipine 
group than in the benazepril/HCTZ group (-2.03 ± 1 4.2 
vs -13.64 ± 16.1 mL/min, p  0.0001). Again, a greater 
reduction in proteinuria, as observed in the benazepril/HCTZ 
arm of GUARD, does not necessarily translate into greater 
renoprotection, as expressed by the slope of GFR reduction.
Further in favor of the ACE inhibitor/CCB combination, 
the recently published ACCOMPLISH trial132 demonstrated a 
striking superiority of the benazepril/amlodipine combination, 
as compared with benazepril/HCTZ, in reducing CV events 
in 11,506 hypertensive patients at high CV risk, 60% of Vascular Health and Risk Management 2009:5 423
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whom were diabetics. After a mean of 30 months of treatment 
exposure, the primary outcome, which was defined as the 
composite of a CV event and death from CV causes, occurred 
in 552 patients (9.6%) in the benazepril/amlodipine group as 
compared with 679 patients (11.8%) in the benazepril/HCTZ 
group (HR 0.80, p  0.001). For the secondary endpoint of 
death from CV causes plus nonfatal MI and non-fatal stroke, 
there were 288 events (5%) in the first group as compared 
with 364 (6.3%) in the second group (HR 0.79, p = 0.002); 
similarly, for the secondary endpoint of CV events, there 
were 494 events (8.6%) in the benazepril/amlodipine arm 
versus 592 (10.3%) in the benazepril/HCTZ arm (HR 0.83, 
p = 0.002).
In conclusion, emerging evidence strongly supports 
the use of an ACE inhibitor/CCB combination in high-risk 
patients. Because more than 75% of hypertensive patients 
with type 2 diabetes will require a combination therapy to 
adequately control BP,17,153 an ACE inhibitor/CCB association 
may be the first choice for controlling BP in hypertensive 
patients with type 2 diabetes, providing at the same time both 
reno- and cardioprotection.
Disclosures
The authors disclose no conflicts of interest.
References
  1.  Steinbrook R. Facing the Diabetes Epidemic – Mandatory Reporting 
of Glycosylated Hemoglobin Values in New York City. N Engl J Med. 
2006;354(6):545–548.
  2.  Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of 
diabetes: estimates for the year 2000 and projections for 2030. Diabetes 
Care. 2004;27(5):1047–1053.
  3.  Stults B, Jones RE. Management of Hypertension in Diabetes. Diabetes 
Spectr. 2006;19(1):25–31.
  4.  DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted 
syndrome responsible for NIDDM, obesity, hypertension, dyslip-
idemia, and atherosclerotic cardiovascular disease. Diabetes Care. 
1991;14(3):173–194.
  5.  Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, 
risk factor for cardiovascular disease. Vasc Med. 2002;7(1):35–43.
  6.  Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the 
Management of Arterial Hypertension: The Task Force for the Manage-
ment of Arterial Hypertension of the European Society of Hypertension 
(ESH) and of the European Society of Cardiology (ESC). J Hypertens. 
2007;25(6):1105–1187.
  7.  Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: 
epidemiology, pathophysiology, and management. JAMA. 2002; 
287(19):2570–2581.
  8.  Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardio-
vascular disease: an update. Hypertension. 2001;37(4):1053–1059.
  9.  Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke 
statistics – 2007 update: a report from the American Heart Association 
Statistics Committee and Stroke Statistics Subcommittee. Circulation. 
2007;115(5):e69–e171.
10.  Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a 
strong, independent risk for atrial fibrillation and flutter in addition to 
other cardiovascular disease. Int J Cardiol. 2005;105(3):315–318.
11.  Tomson C, Ford D, Ansell D. The UK Renal Registry: an overview. 
Br J Hosp Med (Lond). 2008;69(10):548–549.
12.  MMWR WR. Racial differences in trends of end-stage renal disease, by 
primary diagnosis – United States, 1994–2004. MMWR Morb Mortal 
Wkly Rep. 2007;56(11):253–256.
13.  Thomas MC, Atkins RC. Blood pressure lowering for the prevention and 
treatment of diabetic kidney disease. Drugs. 2006;66(17):2213–2234.
14.  Fong DS, Aiello LP, Ferris FL, 3rd Klein R. Diabetic retinopathy. 
Diabetes Care. 2004;27(10):2540–2553.
15.  Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and 
diabetic neuropathy. N Engl J Med. 2005;352(4):341–350.
16.  MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and 
coronary heart disease. Part 1, Prolonged differences in blood pressure: 
prospective observational studies corrected for the regression dilution 
bias. Lancet. 1990;335(8692):765–774.
17.  Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint 
National Committee on Prevention, Detection, Evaluation, and Treat-
ment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252.
18.  American Diabetes Association SG. Standards of medical care in 
diabetes – 2008. Diabetes Care. 2008;31 Suppl 1:S12–S54.
19.  UKPDS SG. Tight blood pressure control and risk of macrovascular 
and microvascular complications in type 2 diabetes: UKPDS 38. UK 
Prospective Diabetes Study Group. BMJ. 1998;317(7160):703–713.
20.  Prisant LM, Weir MR, Papademetriou V, et al. Low-dose drug combina-
tion therapy: an alternative first-line approach to hypertension treatment. 
Am Heart J. 1995;130(2):359–366.
21.  Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combi-
nation treatment with blood pressure lowering drugs: analysis of 354 
randomised trials. BMJ 2003;326(7404):1427.
22.  Lacourciere Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and 
tolerability of two fixed-dose combinations of valsartan and hydrochlo-
rothiazide compared with valsartan monotherapy in patients with stage 
2 or 3 systolic hypertension: an 8-week, randomized, double-blind, 
parallel-group trial. Clin Ther. 2005;27(7):1013–1021.
23.  Taylor AA. Combination drug treatment of hypertension: have we come 
full circle? Curr Cardiol Rep. 2004;6(6):421–426.
24.  Epstein M, Bakris G. Newer approaches to antihypertensive therapy. 
Use of fixed-dose combination therapy. Arch Intern Med. 1996;156(17): 
1969–1978.
25.  Frank J. Managing hypertension using combination therapy. Am Fam 
Physician. 2008;77(9):1279–1286.
26.  Williams B, Shaw A, Durrant R, Crinson I, Pagliari C, de Lusignan S. 
Patient perspectives on multiple medications versus combined pills: a 
qualitative study. QJM. 2005;98(12):885–893.
27.  HOPE and micro-HOPE, SG. Effects of ramipril on cardiovascular 
and microvascular outcomes in people with diabetes mellitus: results 
of the HOPE study and MICRO-HOPE substudy. Heart Outcomes 
Prevention Evaluation Study Investigators. Lancet. 2000;355(9200): 
253–259.
28.  Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A. Reduced 
cardiovascular morbidity and mortality in hypertensive diabetic patients 
on first-line therapy with an ACE inhibitor compared with a diuretic/
beta-blocker-based treatment regimen: a subanalysis of the Captopril 
Prevention Project. Diabetes Care. 2001;24(12):2091–2096.
29.  Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril 
Versus Amlodipine Cardiovascular Events Randomized Trial 
(FACET) in patients with hypertension and NIDDM. Diabetes Care. 
1998;21(4):597–603.
30.  Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, 
Schrier RW. The effect of nisoldipine as compared with enalapril on 
cardiovascular outcomes in patients with non-insulin-dependent diabetes 
and hypertension. N Engl J Med. 1998;338(10):645–652.
31.  Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-
lowering regimens on major cardiovascular events in individuals 
with and without diabetes mellitus: results of prospectively designed 
overviews of randomized trials. Arch Intern Med. 2005;165(12): 
1410–1419.Vascular Health and Risk Management 2009:5 424
Reboldi et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
32.  Arauz-Pacheco C, Parrott MA, Raskin P. Hypertension management 
in adults with diabetes. Diabetes Care. 2004;27 Suppl 1:S65–S67.
33.  Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan 
in patients with type 2 diabetes mellitus: a blood pressure-independent 
effect. Circulation. 2002;106(6):672–678.
34.  Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on 
renal and cardiovascular outcomes in patients with type 2 diabetes and 
nephropathy. N Engl J Med. 2001;345(12):861–869.
35.  Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the 
angiotensin-receptor antagonist irbesartan in patients with nephropathy 
due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860.
36.  Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, 
Arner P. The effect of irbesartan on the development of diabetic 
nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 
345(12):870–878.
37.  Barnett A. Preventing renal complications in type 2 diabetes: results 
of the diabetics exposed to telmisartan and enalapril trial. J Am Soc 
Nephrol. 2006;17(4 Suppl 2):S132–S135.
38.  Palmer BF. Improving BP control with combined renin-angiotensin 
system blockade and thiazide diuretics in hypertensive patients with 
diabetes mellitus or kidney disease. Am J Cardiovasc Drugs. 2008; 
8(1):9–14.
39.  Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in 
antihypertensive treatment of type 2 diabetes, impaired fasting glucose 
concentration, and normoglycemia: Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch 
Intern Med. 2005;165(12):1401–1409.
40.  Palmer BF. Renal dysfunction complicating the treatment of hyperten-
sion. N Engl J Med. 2002;347(16):1256–1261.
41.  Kjeldsen SE, Os I, Hoieggen A, Beckey K, Gleim GW, Oparil S. 
Fixed-dose combinations in the management of hypertension: defining 
the place of angiotensin receptor antagonists and hydrochlorothiazide. 
Am J Cardiovasc Drugs. 2005;5(1):17–22.
42.  Vaughan ED Jr, Carey RM, Peach MJ, Ackerly JA, Ayers CR. The 
renin response to diuretic therapyl A limitation of antihypertensive 
potential. Circ Res. 1978;42(3):376–381.
43.  Greenberg A. Diuretic complications. Am J Med Sci. 2000;319(1):10–24.
44.  Wilcox CS. Metabolic and adverse effects of diuretics. Semin Nephrol/ 
1999;19(6):557–568.
45.  Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, 
potassium, and the development of diabetes: a quantitative review. 
Hypertension. 2006;48(2):219–224.
46.  Koster JC, Remedi MS, Masia R, Patton B, Tong A, Nichols CG. 
Expression of ATP-insensitive KATP channels in pancreatic beta-cells 
underlies a spectrum of diabetic phenotypes. Diabetes. 2006;55(11): 
2957–2964.
47.  Shafi T, Appel LJ, Miller ER 3rd, Klag MJ, Parekh RS. Changes in 
serum potassium mediate thiazide-induced diabetes. Hypertension. 
2008;52(6):1022–1029.
48.  Eriksson JW, Jansson PA, Carlberg B, et al. Hydrochlorothiazide, but not 
Candesartan, aggravates insulin resistance and causes visceral and hepatic 
fat accumulation: the mechanisms for the diabetes preventing effect of 
Candesartan (MEDICA) Study. Hypertension. 2008;52(6):1030–1037.
49.  Carter BL, Einhorn PT, Brands M, et al. Thiazide-induced dysglycemia: 
call for research from a working group from the national heart, lung, 
and blood institute. Hypertension. 2008;52(1):30–36.
50.  Asmar RG, London GM, O’Rourke ME, Safar ME. Improvement in 
blood pressure, arterial stiffness and wave reflections with a very-low-
dose perindopril/indapamide combination in hypertensive patient: a 
comparison with atenolol. Hypertension. 2001;38(4):922–926.
51.  Chanudet X, De Champvallins M. Antihypertensive efficacy and 
tolerability of low-dose perindopril/indapamide combination compared 
with losartan in the treatment of essential hypertension. Int J Clin Pract. 
2001;55(4):233–239.
52.  Corea L, Bentivoglio M, Verdecchia P. Low-dose captopril therapy in 
mild and moderate hypertension. Randomized comparison of twice daily 
vs three times daily doses. Hypertension. 1983;5(5Pt 2):III157–159.
53.  Vidt DG. A controlled multiclinic study to compare the antihyperten-
sive effects of MK-421, hydrochlorothiazide, and MK-421 combined 
with hydrochlorothiazide in patients with mild to moderate essential 
hypertension. J Hypertens Suppl. 1984;2(2):S81–S88.
54.  Esnault VL, Ekhlas A, Delcroix C, Moutel MG, Nguyen JM. Diuretic 
and enhanced sodium restriction results in improved antiproteinuric 
response to RAS blocking agents. J Am Soc Nephrol. 2005;16(2): 
474–481.
55.  Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The 
blunting of the antiproteinuric efficacy of ACE inhibition by high 
sodium intake can be restored by hydrochlorothiazide. Nephrol Dial 
Transplant. 1998;13(7):1682–1685.
56.  Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and 
variability of the antiproteinuric effect of ACE inhibition by lisinopril. 
Kidney Int. 1989;36(2):272–279.
57.  Jones-Burton C, Mishra SI, Fink JC, et al. An in-depth review of the 
evidence linking dietary salt intake and progression of chronic kidney 
disease. Am J Nephrol. 2006;26(3):268–275.
58.  Weinberger MH. Blood pressure and metabolic responses to hydro-
chlorothiazide, captopril, and the combination in black and white 
mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol. 1985; 
7 Suppl 1:S52–S55.
59.  Opie L. Angiotensin-converting enzyme inhibitors: the advance 
continues. Third Edition, University of Cape Town Press. Chapter 3, 
1999. p. 64–67. Chapter 10, p. 222–224.
60.  Jauch KW, Hartl W, Guenther B, Wicklmayr M, Rett K, Dietze G. 
Captopril enhances insulin responsiveness of forearm muscle tis-
sue in non-insulin-dependent diabetes mellitus. Eur J Clin Invest. 
1987;17(5):448–454.
61.  Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J. 
Effect of captopril on glucose concentration. Possible role of aug-
mented postprandial forearm blood flow. Diabetes Care. 1990;13(11): 
1109–1111.
62.  Jacob S, Warth B, Thies R, Gross A, Augustin HJ, Dietze GJ. Acute 
effects of various doses of captopril on glucose metabolism in humans. 
Third International Simposium on ACE inhibition, Amsterdam, The 
Netherlands. 1993.
63.  Henriksen EJ, Jacob S. Angiotensin converting enzyme inhibitors and 
modulation of skeletal muscle insulin resistance. Diabetes Obes Metab. 
2003;5(4):214–222.
64.  Pollare T, Lithell H, Berne CA. Comparison of the effects of 
hydrochlorothiazide and captopril on glucose and lipid metabolism 
in patients with hypertension. N Engl J Med. 1989;321(13): 
868–873.
65.  Vuorinen-Markkola H, Yki-Jarvinen H. Antihypertensive therapy with 
enalapril improves glucose storage and insulin sensitivity in hyperten-
sive patients with non-insulin-dependent diabetes mellitus. Metabolism. 
1995;44(1):85–89.
66.  HOPE SG. Effects of ramipril on cardiovascular and microvascular 
outcomes in people with diabetes mellitus: results of the HOPE study 
and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation 
Study Investigators. Lancet. 2000;355(9200):253–259.
67.  ALLHAT SG. Major outcomes in high-risk hypertensive patients 
randomized to angiotensin-converting enzyme inhibitor or calcium 
channel blocker vs diuretic: The Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 
2002;288(23):2981–2997.
68.  Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihy-
pertensive drugs: a network meta-analysis. Lancet. 2007;369(9557): 
201–207.
69.  Weinberger MH. Influence of an angiotensin converting-enzyme inhibi-
tor on diuretic-induced metabolic effects in hypertension. Hypertension. 
1983;5(5Pt 2):III132–138.
70.  Shamiss A, Carroll J, Peleg E, Grossman E, Rosenthal T. The effect of 
enalapril with and without hydrochlorothiazide on insulin sensitivity and 
other metabolic abnormalities of hypertensive patients with NIDDM. 
Am J Hypertens. 1995;8(3):276–281.Vascular Health and Risk Management 2009:5 425
ACe inhibitor combinations in type 2 diabetes Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
71.  Parati G, omboni S, Malacco E. Antihypertensive efficacy of zofenopril 
and hydrochlorothiazide and their different combinations assessed by 
24 h ambulatory blood pressure monitoring. Journal of Hypertension 
Supplement 2. 2005;S309.
72.  Hunter SJ, Wiggam MI, Ennis CN, et al. Comparison of effects of 
captopril used either alone or in combination with a thiazide diuretic on 
insulin action in hypertensive Type 2 diabetic patients: a double-blind 
crossover study. Diabet Med. 1999;16(6):482–487.
73.  McLaughlin DM, Atkinson AB, Ennis CN, et al. Comparison of 
effects of combined ACE inhibitor and low-dose thiazide diuretic 
with ACE inhibitor alone on insulin action in patients with hyperten-
sion and Type 2 diabetes: a double-blind crossover study. Diabet Med 
2008;25(5):631–634.
74.  Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination 
of perindopril and indapamide on macrovascular and microvascular 
outcomes in patients with type 2 diabetes mellitus (the ADVANCE 
trial): a randomised controlled trial. Lancet. 2007;370(9590): 
829–840.
75.  Mogensen CE, Viberti G, Halimi S, et al. Effect of Low-Dose 
Perindopril/Indapamide on Albuminuria in Diabetes: Preterax in 
Albuminuria Regression: PREMIER. Hypertension. 2003;41(5): 
1063–1071.
76.  PROGRESS SG. Effects of a perindopril-based blood pressure lower-
ing regimen on cardiac outcomes among patients with cerebrovascular 
disease. Eur Heart J. 2003;24(5):475–484.
77.  Berthet K, Neal BC, Chalmers JP, et al. Reductions in the risks of 
recurrent stroke in patients with and without diabetes: The PROGRESS 
Trial. Blood Pressure. 2004;13(1):7–13.
78.  Chan JC, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R. 
Comparison of enalapril and nifedipine in treating non-insulin depen-
dent diabetes associated with hypertension: one year analysis. BMJ. 
1992;305(6860):981–985.
79.  Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control 
and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 
2008;358(24):2560–2572.
80.  Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and 
new antihypertensive drugs in elderly patients: cardiovascular mortality 
and morbidity the Swedish Trial in Old Patients with Hypertension-2 
study. Lancet. 1999;354(9192):1751–1756.
81.  Nosadini R, Tonolo G. Cardiovascular and renal protection in type 2 
diabetes mellitus: the role of calcium channel blockers. J Am Soc 
Nephrol. 2002;13 Suppl 3:S216–S223.
82.  Opie LH. Calcium channel blockers in hypertension: reappraisal after 
new trials and major meta-analyses. Am J Hypertens. 2001;14(10): 
1074–1081.
83.  Avanzini F, Tognoni G. INSIGHT and NORDIL. International Nife-
dipine GITS study: Intervention as a Goal in Hypertension Treatment. 
Nordic Diltiazem Study. Lancet. 2000;356(9245):1927–8; author reply 
1928–1929.
84.  Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the 
progression of atherosclerosis and the occurrence of clinical events. 
PREVENT Investigators. Circulation. 2000;102(13):1503–1510.
85.  Zanchetti A, Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A. 
The Verapamil in Hypertension and Atherosclerosis Study (VHAS): 
results of long-term randomized treatment with either verapamil 
or chlorthalidone on carotid intima-media thickness. J Hypertens. 
1998;16(11):1667–1676.
86.  Folts JD, Schafer AI, Loscalzo J, Willerson JT, Muller JE. A perspec-
tive on the potential problems with aspirin as an antithrombotic agent: 
a comparison of studies in an animal model with clinical trials. J Am 
Coll Cardiol. 1999;33(2):295–303.
87.  Pumphrey CW, Fuster V, Dewanjee MK, Chesebro JH, Vlietstra 
RE, Kaye MP. Comparison of the antithrombotic action of calcium 
antagonist drugs with dipyridamole in dogs. Am J Cardiol. 1983;51(3): 
591–595.
88.  Fogari R. Ankle oedema and sympathetic activation. Drugs. 2005; 
65 Suppl 2:21–27.
  89.  Fogari R, Zoppi A, Corradi L, Preti P, Malalamani GD, Mugellini A. 
Effects of different dihydropyridine calcium antagonists on plasma 
norepinephrine in essential hypertension. J Hypertens. 2000;18(12): 
1871–1875.
  90.  Smith AC, Toto R, Bakris GL. Differential effects of calcium channel 
blockers on size selectivity of proteinuria in diabetic glomerulopathy. 
Kidney Int. 1998;54(3):889–896.
  91.  Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T. Disparate 
effects of calcium antagonists on renal microcirculation. Hypertens 
Res. 1996;19(1):31–36.
  92.  Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T. Role 
of actions of calcium antagonists on efferent arterioles – with special 
references to glomerular hypertension. Am J Nephrol. 2003;23(4): 
229–244.
  93.  Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T. Ca2+ 
channel subtypes and pharmacology in the kidney. Circ Res. 2007; 
100(3):342–353.
  94.  Harris D, Thomas M, Johnson D, Nicholls K, Gillin A. The CARI 
guidelines. Prevention of progression of kidney disease. Nephrology 
(Carlton). 2006;11 Suppl 1:S2–197.
  95.  Brouwer RM, Bolli P, Erne P, Conen D, Kiowski W, Buhler FR. 
Antihypertensive treatment using calcium antagonists in combination 
with captopril rather than diuretics. J Cardiovasc Pharmacol. 1985; 
7 Suppl 1:S88–S91.
  96.  Chrysant SG, Bakris GL. Amlodipine/benazepril combination therapy 
for hypertensive patients nonresponsive to benazepril monotherapy. 
Am J Hypertens. 2004;17(7):590–596.
  97.  Cushman WC, Cohen JD, Jones RP, Marbury TC, Rhoades RB, 
Smith LK. Comparison of the fixed combination of enalapril/diltiazem 
ER and their monotherapies in stage 1 to 3 essential hypertension. 
Am J Hypertens. 1998;11(1Pt 1):23–30.
  98.  Fitscha P, Meisner W, Hitzenberger G. Evaluation of isradipine 
and captopril alone or in combination for the treatment of hyperten-
sion. J Cardiovasc Pharmacol. 1991;18 Suppl 3:S12–S14.
  99.  Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, 
Baron M. Initial angiotensin-converting enzyme inhibitor/calcium 
channel blocker combination therapy achieves superior blood pressure 
control compared with calcium channel blocker monotherapy in 
patients with stage 2 hypertension. Am J Hypertens. 2004;17(6): 
495–501.
100.  Mancia G, Omboni S, Grassi G. Combination treatment in hyper-
tension: the VeraTran Study. Am J Hypertens. 1997;10(7Pt 2): 
153S–158S.
101.  Neutel JM, Smith DH, Weber MA, Schofield L, Purkayastha D, 
Gatlin M. Efficacy of combination therapy for systolic blood pres-
sure in patients with severe systolic hypertension: the Systolic 
Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) 
study. J Clin Hypertens (Greenwich). 2005;7(11):641–646; quiz   
647–648.
102.  Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, 
randomized, double-blind, placebo-controlled, parallel-group studies 
evaluating the efficacy and tolerability of amlodipine and valsartan 
in combination and as monotherapy in adult patients with mild to 
moderate essential hypertension. Clin Ther. 2007;29(4):563–580.
103.  Tedesco MA, Natale F, Calabro R. Effects of monotherapy and 
combination therapy on blood pressure control and target organ 
damage: a randomized prospective intervention study in a large 
population of hypertensive patients. J Clin Hypertens (Greenwich). 
2006;8(9):634–641.
104.  Ferrier C, Ferrari P, Weidmann P, Keller U, Beretta-Piccoli C, 
Riesen WF. Antihypertensive therapy with Ca2+. Antagonist verapamil 
and/or ACE inhibitor enalapril in NIDDM patients. Diabetes Care. 
1991;14(10):911–914.
105.  Bakris G, Molitch M, Hewkin A, et al. Differences in glucose 
tolerance between fixed-dose antihypertensive drug combinations 
in people with metabolic syndrome. Diabetes Care. 2006;29(12): 
2592–2597.Vascular Health and Risk Management 2009:5 426
Reboldi et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
106.  Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular 
events with an antihypertensive regimen of amlodipine adding 
perindopril as required versus atenolol adding bendroflumethiazide as 
required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood 
Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised 
controlled trial. Lancet. 2005;366(9489):895–906.
107.  Rubio-Guerra AF, Arceo-Navarro A, Vargas-Ayala G, Rodriguez-
Lopez L, Lozano-Nuevo JJ, Gomez-Harper CT. The effect of 
trandolapril and its fixed-dose combination with verapamil on 
proteinuria in normotensive adults with type 2 diabetes. Diabetes 
Care. 2004;27(7):1688–1691.
108.  Fogari R, Derosa G, Zoppi A, et al. Effect of delapril/manidipine 
vs olmesartan/ hydrochlorothiazide combination on insulin sensi-
tivity and fibrinogen in obese hypertensive patients. Intern Med. 
2008;47(5):361–366.
109.  Baron AD, Brechtel G, Wallace P, Edelman SV. Rates and tissue sites 
of non-insulin- and insulin-mediated glucose uptake in humans. Am J 
Physiol. 1988;255(6 Pt 1):E769–E774.
110.  Draznin B, Sussman KE, Eckel RH, Kao M, Yost T, Sherman NA. 
Possible role of cytosolic free calcium concentrations in mediating 
insulin resistance of obesity and hyperinsulinemia. J Clin Invest. 
1988;82(6):1848–1852.
111.  Cheng A, Frishman WH. Use of angiotensin-converting enzyme 
inhibitors as monotherapy and in combination with diuretics and 
calcium channel blockers. J Clin Pharmacol. 1998;38(6):477–491.
112.  Frishman WH, Ram CV, McMahon FG, et al. Comparison of 
amlodipine and benazepril monotherapy to amlodipine plus benazepril 
in patients with systemic hypertension: a randomized, double-blind, 
placebo-controlled, parallel-group study. The Benazepril/Amlodipine 
Study Group. J Clin Pharmacol. 1995;35(11):1060–1066.
113.  Kaplan NM. Implications for cost-effectiveness. Combination therapy 
for systemic hypertension. Am J Cardiol. 1995;76(8):595–597.
114.  Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P. 
Effects of different ACE inhibitor combinations on albuminuria: 
results of the GUARD study. Kidney Int. 2008;73(11):1303–1309.
115.  Mital S, Loke KE, Slater JP, Addonizio L, Gersony WM, Hintze TH. 
Synergy of amlodipine and angiotensin-converting enzyme inhibitors 
in regulating myocardial oxygen consumption in normal canine and 
failing human hearts. Am J Cardiol. 1999;83(12A):92H–98H.
116.  Siragy HM, Xue C, Webb RL. Beneficial effects of combined 
benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-
alpha production after cardiac ischemia. J Cardiovasc Pharmacol. 
2006;47(5):636–642.
117.  Zhang X, Xu X, Nasjletti A, Hintze TH. Amlodipine enhances NO 
production induced by an ACE inhibitor through a kinin-mediated 
mechanism in canine coronary microvessels. J Cardiovasc Pharmacol. 
2000;35(2):195–202.
118.  Weir MR. Targeting mechanisms of hypertensive vascular disease with 
dual calcium channel and renin-angiotensin system blockade. J Hum 
Hypertens. 2007;21(10):770–779.
119.  Fogari R, Preti P, Lazzari P, et al. Effect of benazepril amlodipine 
combination on fibrinolysis in hypertensive diabetic patients. Eur J   
Clin Pharmacol. 2003;59(4):271–275.
120.  Neutel JM, Smith DH, Weber MA. Effect of antihypertensive mono-
therapy and combination therapy on arterial distensibility and left 
ventricular mass. Am J Hypertens. 2004;17(1):37–42.
121.  Winer N, Folker A, Murphy JA, et al. Effect of fixed-dose 
ACE-inhibitor/calcium channel blocker combination therapy vs 
ACE-inhibitor monotherapy on arterial compliance in hypertensive 
patients with type 2 diabetes. Prev Cardiol. 2005;8(2):87–92.
122.  Bakris GL, Weir MR. Achieving goal blood pressure in patients 
with type 2 diabetes: conventional versus fixed-dose combination 
approaches. J Clin Hypertens (Greenwich). 2003;5(3):202–209.
123.  Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine 
versus hydrochlorothiazide as add-on to enalapril in diabetic popu-
lations with uncontrolled hypertension. J Hypertens. 2006;24(1): 
185–192.
124.  Tobe S, Kawecka-Jaszcz K, Zannad F, Vetrovec G, Patni R, Shi H. 
Amlodipine added to quinapril vs quinapril alone for the treatment of 
hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial. 
J Clin Hypertens (Greenwich). 2007;9(2):120–127.
125.  Roca-Cusachs A, Schmieder RE, Triposkiadis F, et al. Efficacy of 
manidipine/delapril versus losartan/hydrochlorothiazide fixed com-
binations in patients with hypertension and diabetes. J Hypertens. 
2008;26(4):813–818.
126.  Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive 
blood-pressure lowering and low-dose aspirin in patients with hyper-
tension: principal results of the Hypertension Optimal Treatment 
(HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118): 
1755–1762.
127.  Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-
channel blockade in older patients with diabetes and systolic hyperten-
sion. Systolic Hypertension in Europe Trial Investigators. N Engl J 
Med. 1999;340(9):677–684.
128.  Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium 
antagonist vs a non-calcium antagonist hypertension treatment strategy 
for patients with coronary artery disease. The International Verapamil-
Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 
2003;290(21):2805–2816.
129.  Bakris GL, Gaxiola E, Messerli FH, et al. Clinical Outcomes in the 
Diabetes Cohort of the International Verapamil SR-Trandolapril Study. 
Hypertension. 2004;44(5):637–642.
130.  Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria 
in type 2 diabetes. N Engl J Med. 2004;351(19):1941–1951.
131.  Ostergren J, Poulter NR, Sever PS, et al. The Anglo-Scandinavian 
Cardiac Outcomes Trial: blood pressure-lowering limb: effects in 
patients with type II diabetes. J Hypertens. 2008;26(11):2103–2111.
132.  Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine 
or hydrochlorothiazide for hypertension in high-risk patients. N Engl 
J Med. 2008;359(23):2417–2428.
133.  Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE 
inhibitor/calcium antagonist combination on proteinuria in diabetic 
nephropathy. Kidney Int. 1998;54(4):1283–1289.
134.  Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine fosinopril 
combination on microalbuminuria in hypertensive type 2 diabetic 
patients. Am J Hypertens. 2002;15(12):1042–1049.
135.  Martinez-Martin FJ, Saiz-Satjes M. Add-on manidipine versus 
amlodipine in diabetic patients with hypertension and microalbuminuria: 
the AMANDHA study. Expert Rev Cardiovasc Ther. 2008;6(10): 
1347–1355.
136.  Perazella MA, Setaro JF. Renin-angiotensin-aldosterone system: 
fundamental aspects and clinical implications in renal and cardiovas-
cular disorders. J Nucl Cardiol. 2003;10(2):184–196.
137.  Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-
angiotensin system and cardiovascular risk. Lancet. 2007;369(9568): 
1208–1219.
138.  McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, 
enalapril, and their combination in congestive heart failure: ran-
domized evaluation of strategies for left ventricular dysfunction 
(RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. 
Circulation. 1999;100(10):1056–1064.
139.  Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or 
both in myocardial infarction complicated by heart failure, left ventric-
ular dysfunction, or both. N Engl J Med. 2003;349(20):1893–1906.
140.  Aguilar D, Solomon SD, Kober L, et al. Newly diagnosed and 
previously known diabetes mellitus and 1-year outcomes of acute 
myocardial infarction: the VALsartan In Acute myocardial iNfarcTion 
(VALIANT) trial. Circulation. 2004;110(12):1572–158.
141.  Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at 
high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559.
142.  Mann JFE, Schmieder RE, McQueen M, et al. Renal outcomes 
with telmisartan, ramipril, or both, in people at high vascular risk 
(the ONTARGET study): a multicentre, randomised, double-blind, 
controlled trial. The Lancet. 2008;372(9638):547–553.Vascular Health and Risk Management 2009:5
Vascular Health and Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/vascular-health-and-risk-management-journal
Vascular Health and Risk Management is an international, peer-
reviewed journal of therapeutics and risk management, focusing on 
concise rapid reporting of clinical studies on the processes involved 
in the maintenance of vascular health; the monitoring, prevention and 
treatment of vascular disease and its sequelae; and the involvement of 
metabolic disorders, particularly diabetes. This journal is indexed on 
PubMed Central and MedLine. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
427
ACe inhibitor combinations in type 2 diabetes Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
143.  Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination 
therapy with an ACE inhibitor and an angiotensin receptor blocker 
for diabetic nephropathy: a meta-analysis. Diabet Med. 2007;24(5): 
486–493.
144.  Andersen NH, Poulsen PL, Knudsen ST, et al. Long-term dual 
blockade with candesartan and lisinopril in hypertensive patients 
with diabetes: the CALM II study. Diabetes Care. 2005;28(2): 
273–277.
145.  Tutuncu NB, Gurlek A, Gedik O. Efficacy of ACE inhibitors and ATII 
receptor blockers in patients with microalbuminuria: a prospective 
study. Acta Diabetol. 2001;38(4):157–161.
146.  Onuigbo M, Onuigbo N. Late-onset renal failure from angiotensin 
blockade (LORFFAB) in 100 CKD patients. International Urology 
and Nephrology. 2008;40(1):233–239.
147.  Onuigbo MA. Reno-prevention vs. reno-protection: a critical re-
appraisal of the evidence-base from the large RAAS blockade trials 
after ontarget – a call for more circumspection. QJM. 2008.
148.  Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. The renin 
angiotensin system in the development of cardiovascular disease: role 
of aliskiren in risk reduction. Vasc Health Risk Manag. 2008;4(5): 
971–981.
149.  Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct 
renin inhibitor aliskiren and ramipril alone or in combination in 
patients with diabetes and hypertension. Journal of Renin-Angiotensin-
Aldosterone System. 2007;8(4):190–200.
150.  Taylor A, Tschope D, Kilo C, Ibram G, Fang H, Satlin A. Adding 
aliskiren to ramipril improves 24-hour blood pressure control 
compared to ramipril alone in patients with diabetes and hypertension. 
J Hypertens. 2006;24(Suppl 4):S81. Abstract P4.268.
151.  Rachmani R, Levi Z, Slavachevsky I, Half-Onn E, Ravid M. Effect 
of an alpha-adrenergic blocker, and ACE inhibitor and hydrochloro-
thiazide on blood pressure and on renal function in type 2 diabetic 
patients with hypertension and albuminuria. A randomized cross-over 
study. Nephron. 1998;80(2):175–182.
152.  Fogari R, Corradi L, Zoppi A, et al. Addition of manidipine improves 
the antiproteinuric effect of candesartan in hypertensive patients 
with type II diabetes and microalbuminuria. Am J Hypertens. 2007; 
20(10):1092–1096.
153.  Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in 
adults with hypertension and diabetes: a consensus approach. National 
Kidney Foundation Hypertension and Diabetes Executive Committees 
Working Group. Am J Kidney Dis. 2000;36(3):646–661.